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Abstract 
Objectives: To investigate if HDL cholesterol (HDL-c) could be a biomarker of the degree of severity according to 
prognostic prediction scores in community-acquired pneumonia (CAP) or the development of clinical complications 
such as pleural effusion.
Methods: We included in a retrospective study 107 patients admitted to the hospital that fulfilled diagnostic criteria 
for CAP between the 30th October 2011 and 1st September 2012. HDL-c levels at admission, CAP prognosis scores 
(PSI and CURB65) and clinical outcomes were recorded for the study.
Results: Basal HDL-c levels were not statistically different according to prognostics scores neither PSI nor CURB-
65. Significantly lower levels of HDL-c were also associated to the development of septic shock and admission to 
the intensive care unit. HDL-c were inversely correlated with acute phase reactants CRP (r = −0.585, P < 0.001), ESR 
(r = −0.477, P < 0.001), and leukocytes cell count (r = −0.254, P < 0.009). Patients with pleural effusion showed 
significant lower levels of HDL-c [28.9 (15.5) mg/dl vs. 44.6 (21.1) mg/dl]; P = 0.007. HDL-c is a good predictor of the 
presence of pleural effusion in multivariate analyses and using ROC analyses [AUC = 0.712 (0.591–0.834), P = 0.006]. 
HDL-c levels of 10 mg/dl showed a sensitivity of 97.6 % and a specificity of 82.4 % for the presence of pleural effusion.
Conclusion: Monitoring HDL-c in CAP is an useful serum marker of acute phase response, clinical outcome and the 
presence of pleural effusion.
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Background
Community-acquired pneumonia (CAP) is a major pub-
lic health problem worldwide, with an incidence that 
ranges from 1.6 to 13.4 cases per 1000 inhabitants per 
year, a rate that increase with age and comorbidities. 
CAP is the most frequent infection that causes admis-
sion to a hospital. Different studies have suggested that 
approximately 40  % of patients with CAP are hospital-
ized and around 10  % of these patients are admitted to 
an Intensive Care Unit (ICU). CAP is considered to be 
the leading cause of death among the infections, with a 
rate that ranges between 2 % in ambulatory patients and 
14 % of hospitalized patients. Recent data from the World 
Health Organization from the 2014 showed that infec-
tions of the lower respiratory tract are still the third cause 
of death worldwide and the second cause of life expec-
tancy lost worldwide (www.who.int/gho/publications/
world_health_statistics/EN_WHS2014).
The initial evolution is critical as early clinical failure 
can occur in up to one-quarter of patients with CAP. 
Clinical failure is associated with increased complica-
tions, length of hospital stay and mortality (Wiemken 
et al. 2013).
CAP prediction scores were developed to help phy-
sicians to define severity of disease and likely clinical 
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outcomes of the patient. Almost all of the major decisions 
regarding the management of CAP, including site-of-care 
decisions, revolve around the initial assessment of sever-
ity. The Pneumonia Severity Index (PSI) remains the best 
scoring tool to predict clinical response and long-term 
outcomes (Fine and Auble 1997; Upadhyay and Nieder-
man 2013; Renaud et al. 2009).
Considering the complexity of the PSI calculation, a 
great need exists for simple and more accurate scoring 
tools. Improving these scores will require incorporating 
additional biomarkers, such as procalcitonin, as well as 
the research of new biomarkers associated with early and 
late outcomes (Upadhyay and Niederman 2013).
Another clinical problem not well resolved in pneu-
monias is to detect those patients that will develop com-
plications such as pleural effusion or empyema. Early 
detection of those patients is important since a delay in 
adequate management has prognostic consequences (Fal-
guera et al. 2011).
Recent studies demonstrate that excessive inflamma-
tory response is a major cause of early treatment failure 
of infections (Fernandez-Botran et  al. 2014; Fernández-
Serrano et  al. 2003; Padrones et  al. 2010). Although the 
inflammatory response represents a defense of the host 
to the pathogens, this process is beneficial as long as it 
is limited to the control of local infection. Whenever this 
reaction is over proportioned, systemic inflammation can 
give place to serious complications as the disseminated 
intravascular coagulation, respiratory distress or septic 
shock that leads to an increase in the morbimortality of 
these patients (Rittirsch et al. 2008; Sharifov et al. 2013; 
Steel et al. 2013). Efforts are being made to identify new 
drugs that can modulate this inflammatory response. 
Interestingly, one of the drugs under investigation are 
statins (Takemoto and Liao 2001; McAuley et  al. 2014; 
Criner et al. 2014). Observational studies have suggested 
that patients who were taking statins at the time of the 
development of pneumonia were less likely to develop 
sepsis (Van Lenten et al. 1995), clinical complications or 
death (Yende et  al. 2011; Mortnesen et  al. 2012; Viasus 
et al. 2010). The effect of statins as a coadjuvant therapy 
in CAP has not been studied, so clinical trials are needed 
to determine the impact of statins in patients with CAP 
(Sibila et al. 2013).
Recently it has been discovered that HDL particles pos-
sess anti inflammatory, antioxidant and immunomodula-
tory properties (Norata et al. 2012; Kaji 2013). However, 
the most studied property and, probably, the best under-
stood is the ability of HDL to promote reverse transport 
cholesterol from the periphery to the liver for excretion, 
a mechanism that awards protection against atheroscle-
rosis (Rohatgi et  al. 2014). HDL undergoes pronounced 
structural and functional modifications under acute 
phase response and inflammation (Navab et  al. 2009). 
When pathological processes such as inflammation over-
whelm antioxidant and anti-inflammatory functions of 
HDL, HDL is converted into a dysfunctional, pro-inflam-
matory particle (Van Lenten et al. 1995; Navab et al. 2005, 
2006; Watanabe et al. 2012; Han et al. 2006).
Clinical studies performed during the course of dif-
ferent infectious have concluded that HDL-c levels were 
significantly lower in severally ill patients if an infec-
tion was present (Kumaraswamy et al. 2012; Cappi et al. 
2012; Lekkou et  al. 2014; Vermont et  al. 2005; Chien 
et al. 2005). However, there are few data about patients 
with community-acquired pneumonia (Gruber et  al. 
2009).
Since there is a relationship between HDL, infection 
and the acute phase response we wanted to investigate 
if HDL-c could be a biomarker of success treatment 
in CAP, the degree of severity according to prediction 




This is a retrospective cohort study of patients hospital-
ized because community-acquired pneumonia (CAP) 
in a University Hospital. We identified all the patients 
admitted to the Internal Medicine Department between 
the 30th October of 2011 and the 1st of September of 
2012 with a primary discharge diagnosis of community-
acquired pneumonia.
CAP was defined as an acute illness characterized by 
two or more of the following clinical parameters: fever, 
chills, cough, sputum production, pleuritic pain, and 
signs of lung consolidation, along with the presence of an 
infiltrate on the chest X-ray consistent with the diagnosis.
The inclusion criteria were: over 18 years of age; diag-
nosis of CAP at discharge; a lipid-profile available by 
standard laboratory methods in the first routine hospital 
blood performed at admission.
Patients who did not fulfilled the inclusion criteria or 
with nosocomial pneumonia were not included.
Medical records of all patients were reviewed. All 
patients’ medical data and follow-up records were 
obtained from the inpatient electronic medical records 
system at the hospital with the permission of the institu-
tion according to the institution’s guidelines and ensuring 
the confidentiality of the patients.
The data included: General patient information; 
Comorbid conditions; Clinical findings; Vital signs; Blood 
analyses; Chest radiographs; Microbiology tests; PSI and 
CURB-65 on admission; Charlson comorbidity index; 
Clinical evolution during admission; Follow-up after the 
30th and 90th day.
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Statistical analysis
Data were processed and statistically analyzed using 
SPSS statistical package version 20.0 (Chicago, IL, USA).
Normality distribution of continuous variables was 
checked by Kolmogorov–Smirnov test. Results of con-
tinuous variables are expressed as medians and stand-
ard deviation in parenthesis. Categorical variables are 
expressed as percentage. Frequency comparison was 
performed by Chi square tests. Two-group comparison 
of normally distributed data was performed by Students 
t test. For multigrain comparisons, one-way analysis of 
variance with least square difference for posthoc com-
parison was applied. Bivariate correlation analyses were 
performed using Pearson test.
Multivariate analyses were performed to determine fac-
tors independently associated with pleural effusion and 
HDL levels. Results of multivariate analyses are reported 
as odds ratios with 95 % confidence intervals and P val-
ues. We estimated receiver-operating-characteristics 
(ROC) curve. Sensitivities and specificities for different 
cutoff values were calculated as well positive and negative 
predictive values of the model. All testing was two-tailed 
and P values below 0.05 were considered with a statistical 
significance.
Results
General characteristics of study population
107 patients were included in the study. Briefly, the mean 
age of the patients was 72.64 (16.48) years, which 63.2 % 
were women. The clinical general characteristics are 
shown in Table 1.
The more prevalent symptom of the pneumonias 
included in the study were high temperature (72.9  %), 
cough (73.8 %) and dyspnea (65.4 %) which are the symp-
toms of the classical typical pneumonia with crack-
les (69.2  %) and hypofonesis (25.2  %) in the respiratory 
exam. The more prevalent radiologic pattern was the 
alveolar one (95.3  %) with unilobar extension (77.4  %). 
There was pleural effusion in the 15.9 % of the patients. 
The more prevalent antibiotics used to treat the patients 
were cephalosporin (60.4 %) and macrolides (50 %).
Most of the patients included in the study were classi-
fied with a number four class using PSI (40 %) and in the 
number two using CURB-65 (42.9 %) classification. It is 
noteworthy that although using theses scales there were 
still an important number of patients that were admitted 
to the hospital although a low prognostic stratification.
We did not find significant differences regarding 
HDL-c levels according these prognostics scores neither 
PSI nor CURB-65.
Using the Charlson comorbidity index we found that 
most of the patients showed only one comorbidity 
(34  %) or none comorbidities (12.4  %). Between all the 
comorbidities the more prevalent was the presence of 
COPD (45.8  %), hypertension (40.2  %), diabetes (29  %) 
and dyslipidemia (24.3 %).
Table 1 General characteristics of the population
N 107
Age (years) 72.69 (16.48)
Gender (men) (%) 63.2





Chronic heart failure (%) 17.8
OCPD (%) 45.8





















Global mortality (%) 2.8
Mortality 30-days (%) 0.9













Page 4 of 9Saballs et al. SpringerPlus  (2016) 5:1491 
We found significant differences of HDL-c levels 
according to the presence of comorbidities using Charl-
son index. Interestingly, the lowest levels of HDL-c were 
in the group of patients without any comorbidity (0 
group) with a mean HDL-c of 29.8 (16.6) mmol/dl.
Mortality rates, follow‑up and clinical complications 
regarding HDL‑c levels
We found a low mortality rate in the population of our 
study (2.8 %). The mortality rates after the 30 days of fol-
low up was 0.9 % and after 90 days was 1.9 %. The num-
ber of patients that required a readmission to the hospital 
after 30 days of follow-up was also very low (3.7 %) and 
after 90 days there was no any patient.
We did not find any association between HDL levels 
and mortality rates or the need of readmission to the 
hospital.
The admission to the intensive care unit (ICU) depart-
ment was necessary in 6.5  % (n  =  7) of the patients. 
Shock was diagnosed in 3.7 % (n = 4) and also in 3.7 % 
(n =  4) endotracheal intubation with assisted breathing 
was necessary.
In spite of the low number of patients, we found signifi-
cant differences regarding HDL levels and the presence 
of shock with a mean of 16.25 (10.3) mg/dl respect 43.3 
(20.6), P =  0.024 and the admission to the ICU depart-
ment [23.66 (13.8) respect 43.38 (20.8) mg/dl], P = 0.011 
(Fig. 1a, b).
Association between HDL‑c and acute phase reactants
Bivariate analyses between HDL-c levels and the continue 
variables showed that HDL-c levels were inversely cor-
related with the acute phase reactants CRP (r = −0.585, 
P < 0.001), ESR (r = −0.477, P < 0.001), and leukocytes 
cell count (r = −0.254, P < 0.009; Fig. 2).
In order to investigate those variables that predicted 
HDL-c levels in these cohort of patients we included in 
the linear regression analyses those variables associated 
with HDL metabolism as age, gender, BMI, TG levels, 
hypolipemiant treatment and also the clinical variables 
related to the pneumonia in the univariate analyses with 
lower levels of HDL-c as the presence of empyema, pleu-
ral effusion, shock, ESR, CRP and leukocytes.
We found that HDL-c levels were predicted by age 
[β =  0.665 (0.082–1.247), P =  0.028], ESR [β = −0.445 
(−0.656 to −0.234), P < 0.001] and the presence of pleu-
ral effusion [β = −18.739 (−36.43 to −1.044), P < 0.039] 
(Fig. 3).
Pleural effusion and HDL‑c levels
Patients with pleural effusion showed significant lower 
levels of HDL-c [28.9 (15.5) mg/dl vs. 44.6 (21.1) mg/dl, 
P = 0.007] and in those patients with an empyema there 
was a stronger decrease of HDL-c [18.25 (14.1) mg/dl vs. 
43.2 (20.6) mg/dl, P = 0.019] (Fig. 1b, c).
Clinical differences between patients regarding the 
presence of pleural effusion are described in Table 2. We 
only found significant differences regarding the pres-
ence of pleuritic pain (52.9 respect 15.7 %), higher levels 
of CRP [25.73 (14.6) respect 15.46 (12.27); P < 001] and 
lower levels of LDL-c [74.47 (20.8) respect 95.88 (28.30); 
P = 0.004]. We did not find significant differences regard-
ing age, gender or the presence of different comorbidi-
ties, only a non-significant higher proportion of patients 
with enolism in those patients with pleural effusion [(35.3 
respect 14.8 %) P = 0.054].
To investigate variables that predicted the presence of 
pleural effusion we included in the logistic regression 
model those variables with significant differences regard-
ing the presence of pleural effusion: age, pleuritic pain, 
HDL-c, triglycerides and alcoholism.
We found that age OR 1.053 (1–1.108), P = 0.05; pleu-
ritic pain [OR 11.6113 (2.191–61.553), P = 0.001]; alco-
holism OR 10.370 (1.815–59.24), P = 0.009; and HDL-c 
levels [OR 0.630 (0.409–0.972), P = 0.037] predicted the 
presence of pleural effusion with a negative predictive 
value of the model of 98.8 % (Fig. 4).
To assess the overall diagnosis accuracy we calculated 
the receiver operating characteristics (ROC) for each var-
iable included in the model. We found that only HDL-c 
levels were statistically significant to diagnose the pres-
ence of pleural effusion [AUC  =  0.712 (0.591–0.834), 
P = 0.006] (Fig. 5). HDL levels of 22.5 mg/dl had a sen-
sitivity of 84.7  % and a specificity of 70.6  %, levels of 
10 mg/dl showed a sensitivity of 97.6 % and a specificity 
of 82.4 %.
Discussion
In this study we have shown that low HDL-c levels are 
strongly associated with a worse clinical outcome in 
patients admitted to the hospital because of CAP. This 
observation is particularly relevant regarding the risk 
of hemodynamic inestabilization, the inflammatory 
response or developing pleural effusion.
We found that those patients with a worse clinical 
course that made admission to the intensive care unit 
necessary or presented septic shock showed significant 
lower levels of HDL-c (Fig. 1). Although there was only 
a small number of patients included in our study these 
findings are according to previous results that associate 
HDL as a prognostic serum marker of infection (Gruber 
et  al. 2009; Nandedkar et  al. 2011; Kumaraswamy et  al. 
2012).
Although it is a retrospective observational study we 
collected for the study the first lipid profile performed at 
admission. So we could speculate if low levels of HDL-c 
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are a risk factor for the development of CAP or otherwise 
they decrease during the infection. The last one seems to 
be more relievable, since of several studies have shown 
a decrease of HDL-c levels during sepsis and infection 
(Vermont et  al. 2005; Chien et  al. 2005; Gruber et  al. 
2009). In another observational study in a Swiss cohort of 
patients with CAP, they also demonstrated a decrease of 
HDL-c levels during the admission that normalized after 
the infection (Gruber et al. 2009).
The pathogenic mechanisms to explain how HDL-c 
levels decrease during infection are not yet well 
explained. But it is important to consider that HDL par-
ticles are composed by several apoproteins that seem to 
have a pathogenic role during the acute phase response 
and the innate immune system (Van Lenten et  al. 1995; 
Norata et al. 2012; Kaji 2013; Han et al. 2006; Kumaras-
wamy et al. 2012; Nandedkar et al. 2011). The results of 
our study, agree with these previous studies as we con-
firm this inverse relationship between HDL-c levels and 
the inflammatory serum markers as CRP, ESR and leuko-
cyte cell count. So, the inflammatory regulatory function 
of HDL during the infection seems reliable. We have also 
shown in this study that levels f HDL were determined 
in the multivariate analyses only by ESR, the presence 
of pleural effusion and age and not for those variables 
involved in lipid metabolism.
To understand the pathogenic role of HDL in CAP is 
important to consider the complexity of HDL function 
and composition. It could be useful in order to detect 
those HDL-associated apoproteins that could be poten-
tial biomarkers and therapeutic targets for CAP (Sharifov 
et al. 2013; Han et al. 2006; Guo et al. 2013).
Although, attention the role of HDL or plasma lipids 
during sepsis and lower respiratory tract infections is 
increasing (Chien et al. 2005; Gruber et al. 2009; Hao and 
He 2014; Guo et al. 2013) only few studies were focused 
on the lipids and the presence of pleural effusion (Vaz 
2001; Köktürk et al. 2005).
Fig. 1 Differences between HDL-c levels regarding the presence of ICU admission, shock, pleural effusion or empyema
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The results of our study show that levels of HDL-c 
could be a good biomarker of pleural effusion in patients 
affected by NAC. A level of HDL-c lower than 10 mg/d 
showed a sensitivity of 97.5 % and a specificity of 82.4 %. 
The evolution of hospitalized patients with CAP in the 
first or 3  days is crucial, it is important to detect the 
presence of pleural effusion or the patients at risk of it 
because of the optimal treatment approach is impor-
tant for the course of infection that may include an early 
thoracocentesis or surgical drainage of empyema. For this 
reason we think that determination of HDL-c could be 
easy and useful in the decision-making in the ordinary 
clinical practice.
Fig. 2 Bivariate correlations between HDL-c levels and leukocyte cell count, ESR and CRP
Fig. 3 Linear regression analyses. Variables that predict HDL levels in 
patients with CAP
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It was proposed in few studies that increased perme-
ability of pleura during infection allows the pass of lipids 
from serum to the pleura and they could be useful to dis-
criminate transudate respect exsudate effusion (Kumar-
aswamy et  al. 2012). These could explain the decrease 
of HDL and LDL in the plasma that we found in those 
patients with pleural effusion. But, as we found a strong 
inverse relationship between HDL-c and the inflamma-
tory serum markers as CRP, leukocyte and ESR we can 
elucidate that HDL maybe is not only a specific serum 
marker of pleural effusion (transudate or exsudate) but it 
is a good serum marker of the increased systemic inflam-
matory response of these patients and the organ-specific 
inflammation, in this case, the pleura.
This is a retrospective study so there are some impor-
tant limitations. We have a selection bias because we only 
included those patients affected by CAP admitted into 
the hospital and we don ‘t have data about those patients 
treated in-home or those that were discharged at home 
from the emergency department. But the results seem 
to be relevant. On the other hand, most of the patients 
included in this study showed the typical clinical presen-
tation so misdiagnosis rate seems to be low.
We conclude that the monitoring of HDL-c levels in 
CAP could be useful as serum marker of acute phase 
response after infection and the presence of pleural effu-
sion. Clinical course of CAP is not only influenced by the 
etiologic agent but also influenced by the host inflamma-
tory response. This may be associated with the clinical 
course of the patient and the organ involvement. HDL 
Table 2 Clinical characteristics of  the patients regard-
ing the presence of pleural effusion
* Variables with statistical differences P < 0.05





Age (years) 70.05 (14.7) 73.1 (16.8) NS
Gender, men (%) 58.8 57 NS
TC (mg/dl) 129.3 (28.0) 165.9 (37.4) <0.001*
HDL (mg/dl) 29.88 (15.54) 44.6 (21.6) 0.007*
LDL (mg/dl) 74.5 (20.8) 95.8 (28.3) 0.004*
TG (mg/dl) 125.2 (64.4) 126.3 (72.5) NS
Length of hospital stay (days) 13.2 (6.9) 9.6 (8.4) NS
SBP (mmHg) 127.5 (41.4) 129.8 (22.7) NS
Leukocyte cell count (×103/μl) 17.79 (10.78) 13.72 (7.11) 0.051
CRP 25.7 (14.4) 15.5 (12.3) 0.005*
ESR (mm/h) 90.0 (35.6) 74.3 (31.8) NS
Alb (mg/dl) 4.13 (0.26) 3.55 (0.42) NS
Pleuritic pain 52.9 % 15.7 % 0.002*
Temperature >38 °C (%) 76.5 % 73 % NS
Dyspnea (%) 82.4 62.9 NS
Cough (%) 64.7 76.4 NS
Tabaquism (%) 17.6 20.2 NS
Enolism (%) 35.3 14.8 0.054
Diabetes (%) 30.7 23.5 NS
Hypertension 41.2 41.4 NS
Dyslipidemia (%) 29 11.4 NS
OCPD (%) 41.2 47.2 NS
Congestive heart failure (%) 23.5 16.9 NS
Chronic renal disease (%) 17 9 NS
Statins (%) 11.8 19.3 NS
Corticoids (%) 70.6 68.5 NS
Fig. 4 Logistic regression analyses. Variables that predict the pres-
ence of pleural effusion
Fig. 5 ROC curve. HDL-chol levels predicts pleural effusion
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could add information guiding antibiotic therapy or to 
decide when to admit a patient affected by CAP into the 
hospital or the risk of pleural effusion and empyema.
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